{"groups":[{"description":"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.\n\nMAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.\n\nHyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy\n\nStereotactic radiosurgery: Undergo stereotactic radiosurgery\n\nAlisertib: Given PO\n\nQuality-of-life assessment: Ancillary studies","id":"FG000","title":"Alisertib, Fractionated Stereotactic Radiosurgery"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}